ischemic stroke
Conditions
Interventions
observation group:none
Sponsors
Hubei Aerospace Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Adult subjects (male or female = 40 years) 2.Acute non-disabling ischemic stroke (NIHSS=3) that can be treated with study drug within 24 hours of symptoms onset. Symptom onset is defined by the last see normal principle. 3.TIA (Neurological deficit attributed to focal brain ischemia, with resolution of the deficit within 24 hours of symptom onset), that can be treated with study drug within 24 hours of symptoms onset and with moderate-to-high risk of stroke recurrence (ABCD2 score = 4). 4.Symptom onset is defined by the last see normal principle. 5.Informed consent signed.
Exclusion criteria
Exclusion criteria: 1. Diagnosis of bleeding or other pathological brain diseases according to baseline head CT or MRI 2. No evidence of acute infarction on baseline head CT or MRI 3. Clear indications for anticoagulant therapy (suspected cardiogenic embolism, such as atrial fibrillation, known artificial heart valves, endocarditis, etc.) 4. There are contraindications to clopidogrel, ticagrelor or aspirin 5. History of intracranial hemorrhage 6. Long-term use of non-investigational antiplatelet aggregation agents or non-steroidal anti-inflammatory drugs that affect platelet function is expected 7. Heparin or oral anticoagulants have been used in the previous 10 days Gastrointestinal bleeding or major surgery within the previous 3 months Other planned surgical procedures or interventional treatments may require discontinuation of the investigational drug Other planned surgical procedures or interventional treatments may discontinue use of the investigational drug 11. TIA or minor death caused by angiogenesis or vascular surgery 12. Patients with severe systemic diseases with an expected survival time of less than 1 year 13. Women of childbearing age who do not take effective contraceptive measures and have a positive pregnancy test record 14. Patients undergoing experimental drug or device trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrent stroke; | — |
Secondary
| Measure | Time frame |
|---|---|
| NIHSS(National Institute of Health stroke scale);mRS(Modified Rankin Scale); | — |
Countries
china
Contacts
Public ContactChangsheng Liu
Hubei Aerospace Hospital
Outcome results
None listed